Srinivas Devarakonda
Overview
Explore the profile of Srinivas Devarakonda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
242
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neuendorff N, Khan A, Ullrich F, Yates S, Devarakonda S, Lin R, et al.
J Geriatr Oncol
. 2024 Mar;
15(3):101734.
PMID: 38430810
Cellular therapies, including autologous stem cell transplant (ASCT), allogeneic hematopoietic cell transplantation (alloHCT), and chimeric antigen receptor- (CAR-) T cell therapies are essential treatment modalities for many hematological malignancies. Although...
2.
Kumar S, Callander N, Adekola K, Anderson Jr L, Baljevic M, Baz R, et al.
J Natl Compr Canc Netw
. 2024 Jan;
22(1D):e240001.
PMID: 38244272
The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment,...
3.
Kumar S, Callander N, Adekola K, Anderson Jr L, Baljevic M, Baz R, et al.
J Natl Compr Canc Netw
. 2023 Dec;
21(12):1281-1301.
PMID: 38081133
The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several new options. These include new combinations with second generation proteasome inhibitors (PI); second generation immunomodulators, monoclonal antibodies, CAR...
4.
Khan A, Dvorak K, Zhao Q, Bumma N, Cottini F, Devarakonda S, et al.
Haematologica
. 2023 Jul;
108(12):3477-3479.
PMID: 37439332
No abstract available.
5.
Sharma N, Benson E, Zhao Q, Nunnelee J, Cottini F, Elder P, et al.
Leuk Lymphoma
. 2023 May;
64(7):1315-1321.
PMID: 37199099
The standard preparative regimen for autologous stem cell transplant (ASCT) in multiple myeloma (MM) is 200 mg/m of intravenous melphalan; however, a dose of 140 mg/m is often used when...
6.
Kumar S, Callander N, Adekola K, Anderson Jr L, Baljevic M, Campagnaro E, et al.
J Natl Compr Canc Netw
. 2023 Jan;
21(1):67-81.
PMID: 36652935
Primary systemic light chain amyloidosis (SLCA) is characterized by production of light chains that get converted to amyloid fibrils with an affinity for visceral organs and causing organ dysfunction. The...
7.
Khan A, Ozga M, Bhatt H, Faisal M, Ansari S, Zhao Q, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Dec;
23(3):e182-e189.
PMID: 36581554
Background: The role of salvage autologous hematopoietic cell transplantation (sAHCT2) for patients with relapsed/refractory multiple myeloma (RRMM) in the era of modern therapeutics is unclear. As prospective data is limited,...
8.
Devarakonda S, Sharma N, Efebera Y
Hematology Am Soc Hematol Educ Program
. 2022 Dec;
2022(1):560-568.
PMID: 36485087
The choice of treatment for patients with multiple myeloma (MM) at first relapse/progression is based on many factors: (1) treatment-related factors, which include the regimen used during first induction, the...
9.
Khan A, Yucebay F, Zhao Q, Umyarova E, Cottini F, Bumma N, et al.
Clin Lymphoma Myeloma Leuk
. 2022 Nov;
23(2):e85-e96.
PMID: 36411211
Background: High-dose melphalan (HDM) with autologous hematopoietic cell transplantation (AHCT) after induction chemotherapy is considered standard of care in transplant-eligible patients with newly-diagnosed multiple myeloma (MM). Alkeran melphalan has propylene...
10.
Nunnelee J, Cottini F, Zhao Q, Faisal M, Elder P, Rosko A, et al.
J Clin Med
. 2022 Oct;
11(19).
PMID: 36233663
Maintenance therapy after autologous stem cell transplant (ASCT) in multiple myeloma (MM) is the standard treatment and recommended to be continued until disease progression. However, in the real world, patients...